Company / Capital Expenditures
Perspective Therapeutics, Inc. Capital Expenditures History
FY2013-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$266.0K
FY2022
5-year range
$266.0K / $549.0K
FY2018-FY2022
Trend
-40.1%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures has fluctuated over the past 10 years, ranging from $6,576 in FY2015 to $549,000 in FY2019.
Based on SEC 10-K filings.
$266,000 in FY2022 with a 5-year CAGR of +14.9%.
Declined from $337,000 to $266,000 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -21.5%
- 5-Year CAGR
- +14.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +14.9%, indicating consistent growth.
- In FY2022, capital expenditures decreased 40.1% year-over-year.
- Peak capital expenditures was recorded in FY2019.
- Lowest capital expenditures in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 5.43 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $266.0K | -40.1% |
| FY2021 | $444.0K | +31.8% |
| FY2020 | $337.0K | -38.6% |
| FY2019 | $549.0K | +14.6% |
| FY2018 | $479.0K | +260.2% |
| FY2017 | $133.0K | +598.9% |
| FY2016 | $19.0K | +189.4% |
| FY2015 | $6.6K | +0.0% |
| FY2014 | $6.6K | -88.1% |
| FY2013 | $55.1K | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026